Mode
Text Size
Log in / Sign up
N/A N=49 Prevention

Behavior During Experimentally Induced Pain

Schizophrenia · Major Depression

Enrolled (actual)
49
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Indicators / Minute — 1.925; 0.23; 0.4; 0.45 indicators/minute — p=0.992

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
pain tests (Other)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Centre Hospitalier Esquirol
Primary completion
Dec 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Indicators / Minute
1.925; 0.23; 0.4; 0.45; 0.59; 0.55 0.992

Summary

Numerous factors can influence the processing of pain message: the affective or emotional, the sensorial and the cognitive components. Interindividual variations at the emotional and cognitive levels may interfere with the pain message and the consecutive behavior. Some modifications in these components are observed in psychiatric troubles, but their influences on the behavior to pain have not been studied, although they have been studied in some populations characterized as non communicating, with obvious cognitive degradations (subject with dementia, older, newborns,…).In an other study in course, the past pain experience is explored in relation to results to experimental pain tests, emotional and anxious characteristics. This present pilot study aims at studying the infra-verbal behavioural signs during experimentally induced pain in subjects with schizophrenia, major depression, and controls.

Eligibility Criteria

Inclusion Criteria

  • subjects with psychiatric trouble : diagnosis of schizophrenia or major depression according to the DSM-IV-TR criteria.
  • control subjects : without known psychiatric history.
  • age between 18 and 60.

Exclusion Criteria

  • absence of consent, hospitalization under constraint, absence of health insurance.
  • inability to answer the questionnaires
  • pregnancy
  • antalgic or analgesic treatment
  • allergy to latex
  • non stabilized high blood pressure, bad blood coagulation,
  • peripheral neuropathy, nerve lesion, dermatosis at the superior extremities, muscular lesion or pathology at the upper member level
  • non treated alcohol dependence
  • illegal substance consumption in the past 48 hours
  • participation to an other biomedical study during the 2 weeks before inclusion, and until the pain tests, if this study can interfere with the realization of the objectives
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01594528). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search